• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Left ventricular assist systems and strokes: Statins to the rescue?
The development of durable left ventricular assist systems (LVASs) has been critical in providing an option for management of end-stage heart disease and addressing the increasing gap between demand and supply of donor cardiac allografts for management of end-stage heart disease. The technology also provides an alternative to heart transplantation in many patients. Unfortunately, the long-term use of LVASs has been associated with significant morbidities, the most devastating of which may relate to the thrombogenicity of the artificial devices, leading to ischemic stroke or pump thrombosis.
Source: The Journal of Heart and Lung Transplantation - March 16, 2020 Category: Transplant Surgery Authors: Jignesh K. Patel Tags: EDITORIAL COMMENTARY Source Type: research

Left Ventricular Assist Systems and Strokes- Statins to the Rescue?
The development of durable left ventricular assist systems (LVAS) has been critical in providing an option for management of end-stage heart disease and addressing the increasing gap between demand and supply of donor cardiac allografts for management of end-stage heart disease. The technology also provides an alternative to heart transplantation in many patients. Unfortunately, the long-term use of LVAS has been associated with significant morbidities, the most devastating of which may relate to the thrombogenicity of the artificial devices, leading to ischemic stroke or pump thrombosis.
Source: The Journal of Heart and Lung Transplantation - March 16, 2020 Category: Transplant Surgery Authors: Jignesh Patel Tags: Editorial Source Type: research

Cardiovascular Risk Assessment Before and After Kidney Transplantation
Cardiovascular disease (CVD) is the leading cause of death in dialysis patients and the most common cause of death and allograft loss among kidney transplant recipients. End-stage renal disease (ESRD) is associated with an increased incidence and prevalence of a wide range of CVDs including coronary artery disease, stroke, congestive heart failure, atrial fibrillation, sudden cardiac death, pulmonary hypertension, and valvular heart disease. CVD risk factors are very common in patients with ESRD, and most patients have multiple risk factors. Kidney transplantation is the treatment of choice for patients with ESRD, as a suc...
Source: Cardiology in Review - June 6, 2014 Category: Cardiology Tags: Review Articles Source Type: research

HMG CoA reductase inhibitors (statins) for kidney transplant recipients.
CONCLUSIONS: Statins may reduce cardiovascular events in kidney transplant recipients, although treatment effects are imprecise. Statin treatment has uncertain effects on overall mortality, stroke, kidney function, and toxicity outcomes in kidney transplant recipients. Additional studies would improve our confidence in the treatment benefits and harms of statins on cardiovascular events in this clinical setting. PMID: 24470059 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - February 3, 2014 Category: Journals (General) Authors: Palmer SC, Navaneethan SD, Craig JC, Perkovic V, Johnson DW, Nigwekar SU, Hegbrant J, Strippoli GF Tags: Cochrane Database Syst Rev Source Type: research